

DAFTAR PUSTAKA

- Abouassaly R., Thompson IM., Platz EA., Klein EA. (2012) Epidemiology, etiology, and prevention of prostate cancer, dalam Campbell-Walsh Urology tenth edition (Wein A.J., Kavoussi L.R., Novick A.C., Partin A.W., Peters A.C., eds): 2704 - 2725. Saunders Elsevier, Philadelphia.
- American Cancer Society. Cancer facts & figures 2008. Atlanta: American Cancer Society; 2008.
- Australian Institute of Health and Welfare. Australia's health 2008. Canberra: AIHW; 2008. Cat. no. AUS 99.
- Balk SP, Knudsen KE. AR, the cell cycle, and prostate cancer. Nucl Recept Signal 2008;6:e001.
- Canby-Hagino E, Hernandez J, Brand TC, Thompson I. Looking back at PCPT: looking forward to new paradigms in prostate cancer screening and prevention. Eur Urol 2007; 51:27–33.
- Carlin JR, Höglund P, Eriksson LO, Christofalo P, Gregoire SL, Taylor AM, et al. Disposition and pharmacokinetics of [14C] finasteride after oral administration in humans. Drug Metab Dispos 1992;20:48–55.
- Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J Clin Endocrinol Metab 2004;89:2179–84.
- Damber JE, Aus G. Prostate cancer. Lancet 2008;371: 1710–21.
- Ellem SJ, Schmitt JF, Pedersen JS, Frydenberg M, Risbridger GP. Local aromatase expression in human prostate is altered in malignancy. J Clin Endocrinol Metab 2004;89:2434–41.
- Ellem SJ, Schmitt JF, Pedersen JS, Frydenberg M, Risbridger GP. Local aromatase expression in human prostate is altered in malignancy. J Clin Endocrinol Metab 2004;89:2434–41.

- Eng MH, Charles LG, Ross BD, Chrisp CE, Pienta KJ, Greenberg NM, et al. Early castration reduces prostatic carcinogenesis in transgenic mice. *Urology* 1999;54:1112–9.
- Evans HC, Goa KL. Dutasteride. *Drugs Aging* 2003;20: 905–16.
- Ferlay, J., et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer*, 2015. 136: E359.
- Figg et al., *Drug Management of Prostate Cancer*. Springer 2010; 109-121.
- Gann, P. H., Hennekens, C. H., Ma, J., Longcope, C., and Stampfer, M. J. A prospective study of sex hormone levels and risk of prostate cancer. *J. Natl. Cancer Inst. (Bethesda)*, 88: 1118–1126, 1996.
- Grindstad T, Skjefstad K, Andersen S, Ness N, Nordby Y, Al-Saad S, Fismen S, Donnem T, Khanekkenari MR, Busund L, Bremnes R, Richardsen. Estrogen receptors α and β and aromatase as independent predictors for prostate cancer outcome. *Sci Rep*. 2016; 6: 33114.
- Harada N, Utsumi T, Takagi Y. Tissue-specific expression of the human aromatase cytochrome P-450 gene by alternative use of multiple exons 1 and promoters, and switching of tissue-specific exons 1 in carcinogenesis. *Proc Natl Acad Sci U S A* 1993;90:11312–6.
- Hiramatsu M, Maehara I, Ozaki M, Harada N, Orikasa S, Sasano H. Aromatase in hyperplasia and carcinoma of the human prostate. *Prostate* 1997;31:118–24.
- Huggins C. Effect of orchiectomy and irradiation on cancer of the prostate. *Ann Surg* 1942;115:1192–200.
- Klein EA. Selenium and vitamin E cancer prevention trial. *Ann N Y Acad Sci* 2004;1031:234–41.
- Lazier CB, Thomas LN, Douglas RC, Vessey JP, Rittmaster RS. Dutasteride, the dual 5 α -reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line. *Prostate* 2004;58:130–44.
- Lee SO, Yeon Chun J, Nadiminty N, Trump DL, Ip C, Dong Y, et al. Monomethylated selenium inhibits growth of LNCaP human prostate

cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA). *Prostate* 2006;66:1070–5.

Loblaw DA, Virgo KS, Nam R, Somerfield MR, Ben-Josef E, Mendelson DS, et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. *J Clin Oncol* 2007;25:1596–605.

Lu S, Tsai SY, Tsai MJ. Regulation of androgen-dependent prostatic cancer cell growth: androgen regulation of CDK2, CDK4, and CKI p16 genes. *Cancer Res* 1997;57:4511–6.

Luu-The V, Bélanger A, Labrie F. Androgen biosynthetic pathways in the human prostate. *Best Pract Res Clin Endocrinol Metab* 2008;22:207–21.

Maria McCrohan A, Morrissey C, O’Keane C, Mulligan N, Watson C, Smith J, et al. Effects of the dual 5 alpha-reductase inhibitor dutasteride on apoptosis in primary cultures of prostate cancer epithelial cells and cell lines. *Cancer* 2006; 106:2743–52.

Musquera M, Fleshner NE, Finelli A, Zlotta AR. The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride. *Expert Rev Anticancer Ther* 2008;8:1073–9.

Negri-Cesi P, Poletti A, Colciago A, Magni P, Martini P, Motta M. Presence of 5alpha-reductase isozymes and aromatase in human prostate cancer cells and in benign prostate hyperplastic tissue. *Prostate* 1998;34:283–91.

Prins GS, Korach KS. The role of estrogens and estrogen receptors in normal prostate growth and disease. *Steroids* 2008;73:233–44.

Santen RJ, Petroni GR, Fisch MJ, Myers CE, Theodorescu D, Cohen RB. Use of the aromatase inhibitor anastrozole in the treatment of patients with advanced prostate carcinoma. *Cancer* 2001;92:2095–101.

Smith MR, Kaufman D, George D, Oh WK, Kazanis M, Manola J, et al. Selective aromatase inhibition for patients with androgen-independent prostate carcinoma. *Cancer* 2002;95:1864–8.

- Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. *N Engl J Med* 2003;349: 215–24.
- Tian G, Mook Jr RA, Moss ML, Frye SV. Mechanism of time-dependent inhibition of 5 alpha-reductases by delta 1-4-azasteroids: toward perfection of rates of time-dependent inhibition by using ligand-binding energies. *Biochemistry* 1995;34:13453–9.
- Voigt, K., and Bartsch, W. Intratissular androgens in benign prostatic hyperplasia and prostatic cancer. *J. Steroid Biochem.*, 25: 749–757, 1986.
- Wright AS, Douglas RC, Thomas LN, Lazier CB, Rittmaster RS. Androgen-induced regrowth in the castrated rat ventral prostate: role of 5alpha-reductase. *Endocrinology* 1999;140: 4509–15.
- Wu CP, Gu FL. The prostate in eunuchs. *Prog Clin Biol Res* 1991;370:249–55.
- Zhang Y, Ni J, Messing EM, Chang E, Yang CR, Yeh S. Vitamin E succinate inhibits the function of androgen receptor and the expression of prostate-specific antigen in prostate cancer cells. *Proc Natl Acad Sci U S A* 2002; 99:7408–13.
- Zhao XY, Malloy PJ, Krishnan AV, Swami S, Navone NM, Peehl DM, et al. Glucocorticoids can promote androgenindependent growth of prostate cancer cells through a mutated androgen receptor. *Nat Med* 2000;6:703–6.